Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Expected to Post Q3 2017 Earnings of ($1.10) Per Share

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – Investment analysts at Jefferies Group issued their Q3 2017 earnings per share (EPS) estimates for Atara Biotherapeutics in a research report issued to clients and investors on Tuesday. Jefferies Group analyst M. Raycroft anticipates that the biotechnology company will earn ($1.10) per share for the quarter. Jefferies Group has a “Buy” rating and a $30.00 price objective on the stock. Jefferies Group also issued estimates for Atara Biotherapeutics’ Q4 2017 earnings at ($1.32) EPS, FY2017 earnings at ($4.24) EPS, FY2018 earnings at ($5.25) EPS, FY2019 earnings at ($5.65) EPS, FY2020 earnings at ($5.25) EPS and FY2021 earnings at ($4.17) EPS.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.89) by $0.05.

COPYRIGHT VIOLATION NOTICE: “Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Expected to Post Q3 2017 Earnings of ($1.10) Per Share” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.com-unik.info/2017/08/12/atara-biotherapeutics-inc-nasdaqatra-expected-to-post-q3-2017-earnings-of-1-10-per-share.html.

A number of other brokerages also recently issued reports on ATRA. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. Canaccord Genuity reissued a “buy” rating and issued a $47.00 price target on shares of Atara Biotherapeutics in a report on Friday, April 21st. ValuEngine downgraded shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. Finally, William Blair reissued an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $25.75.

Atara Biotherapeutics (ATRA) opened at 14.75 on Thursday. The firm has a 50-day moving average of $15.02 and a 200 day moving average of $15.89. Atara Biotherapeutics has a 12-month low of $11.80 and a 12-month high of $23.40. The company’s market capitalization is $450.75 million.

In other news, CFO John Mcgrath sold 4,000 shares of the stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $15.11, for a total value of $60,440.00. Following the sale, the chief financial officer now directly owns 113,762 shares of the company’s stock, valued at $1,718,943.82. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Christopher Haqq sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $12.65, for a total transaction of $75,900.00. Following the completion of the transaction, the executive vice president now owns 368,080 shares in the company, valued at $4,656,212. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,308 shares of company stock worth $797,382. Insiders own 16.10% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of ATRA. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Atara Biotherapeutics during the first quarter valued at $132,000. DekaBank Deutsche Girozentrale bought a new position in Atara Biotherapeutics during the first quarter valued at $185,000. American International Group Inc. boosted its position in Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 948 shares during the period. State of Wisconsin Investment Board bought a new position in Atara Biotherapeutics during the second quarter valued at $252,000. Finally, Dimensional Fund Advisors LP boosted its position in Atara Biotherapeutics by 2.9% in the second quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock valued at $304,000 after buying an additional 610 shares during the period. Institutional investors own 81.50% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

What are top analysts saying about Atara Biotherapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Atara Biotherapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit